Recently, we have shown that a novel recombinant bispecific single-chain antibody construct (bscCD19 Â CD3), induces highly efficacious lymphoma-directed cytotoxicity mediated by unstimulated peripheral T lymphocytes. Functional analysis of bscCD193CD3 has so far been exclusively performed with human B lymphoma cell lines and T cells from healthy donors. Here we analysed the properties of bscCD193CD3 using primary B cells and autologous T cells from healthy volunteers or patients with B-cell chronic lymphocytic leukaemia (B-CLL). We show that bscCD193CD3 induces T-cell-mediated depletion of nonmalignant B cells in all four cases and depletion of primary lymphoma cells in 22 out of 25 cases. This effect could be observed at low effector-to-target (E:T) ratios and in the majority of cases without additional activation of autologous T cells by IL-2. Even in samples derived from patients heavily pretreated with different chemotherapy regimens, strong cytotoxic effects of bscCD193CD3 could be observed. The addition of bscCD193CD3 to patients' cells resulted in an upregulation of activation-specific cell surface antigens on autologous T cells and elevated levels of CD95 on lymphoma B cells. Although anti-CD95 antibody CH-11 failed to induce apoptosis in lymphoma cells, we provide evidence that B-CLL cell depletion by bscCD3CD3 is mediated at least in part by apoptosis via the caspase pathway.
Introduction
B-cell chronic lymphocytic leukaemia (B-CLL) is a frequent subtype of low-grade non-Hodgkin's lymphomas (NHL) and the most common leukaemia of adults in Western countries. 1 Although objective remissions can be achieved by various chemotherapy regimens, patients will relapse and ultimately succumb to their disease. Thus, B-CLL cannot be cured by currently available treatment options and novel therapeutic strategies are urgently needed.
A promising new modality that might have the potential to improve the outcome of lymphoma treatment is immunotherapy using antibodies. Application of Campath-1 H, a humanised monoclonal antibody directed against CD52, led to response rates of about 90 and 40% when used in untreated and pretreated CLL, respectively. 2, 3 However, because of its ability to deplete both, B and T cells, toxicity was considerable and led to cellular immunosuppression and subsequent opportunistic infections in most of the heavily treated patients. 3 A chimerised murine/human anti-CD20 antibody (Rituximab) led to response rates of about 50% in certain low-grade lymphomas in phase II clinical trials without pronounced side effects. 4, 5 In B-CLL Rituximab seems to be less efficacious. 6, 7 Thus, although monoclonal antibodies appear to be efficacious in the treatment of NHL further improvement of this new modality is necessary, in particular for the treatment of B-CLL.
From in vitro studies with cell lines, three different effector mechanisms of tumour elimination by antibodies have been proposed: (1) antibody-dependent cellular cytotoxicity (ADCC), (2) complement-mediated lysis, and (3) direct proapoptotic signalling induced by receptor crosslinking. Several sets of data point to ADCC as the major effector mechanism in vivo. 8, 9 ADCC depends on the binding of monoclonal antibodies to Fc receptors on a variety of cell types, mainly monocytes, macrophages and NK cells. Thus, potential drawbacks of this process are triggering of activating as well as inhibitory Fc receptors 8 and the inability of monoclonal antibodies to directly activate T cells, the most potent effectors of cellular immunity.
Because of their dual binding specificity for tumour antigens and signal transducing structures on effector cells (such as the CD3 component of the T-cell receptor complex), bispecific antibodies (bsAbs) provide an effective means of targeting cytotoxic effector cells against tumour cells. 10, 11 For the treatment of B-lineage lymphomas the CD19 antigen seems to be an especially suitable target, since it is expressed in the vast majority of B-cell malignancies, while it is absent from haematopoietic stem cells and plasma cells. 12, 13 BsAbs have been demonstrated to be effective in vitro, 14, 15 and in animal models. 16, 17 Early clinical trials have been undertaken showing safety of these molecules, and clinical responses. [18] [19] [20] [21] [22] Those molecules have been produced by chemical crosslinking of two monoclonal antibodies, hybrid hybridoma (quadroma) technology or renaturation from bacterial inclusion bodies. However, attempts for the large-scale production and purification of bsAbs suffer from low yields, illdefined by-products or laborious purification and refolding procedures. [23] [24] [25] Therefore, more extensive clinical studies are still lacking.
To overcome these problems, we generated a recombinant bispecific single-chain antibody, bscCD19 Â CD3. 26 This minimalistic antibody construct consists of four variable antibody regions in the configuration VL CD19 -VH CD19 -VH CD3 -VL CD3 on a single polypeptide chain. The resulting recombinant 55 kDa molecule produced by CHO cells is secreted in an active form. It specifically binds to CD19 on B cells and CD3 on T cells as confirmed by binding studies on B-and T-cell lines and on primary human lymphocytes. BscCD19 Â CD3 did not bind to cells negative for both antigens. 26 BscCD19 Â CD3 stimulates T-cell proliferation only in the presence of B target cells, suggesting a need for CD3 receptor crosslinking by bscCD19 Â CD3 and B cells. By redirecting primary T cells against CD19-positive lymphoma cell lines, the antibody construct showed significant cytotoxic activity at concentrations of 10-100 pg/ml and low effector: target (E:T) ratios. B lymphoma-directed cytotoxicity could be observed within hours even in the absence of pre-or costimulation of peripheral T lymphocytes. 26 Incubation with parental monoclonal antibodies against CD3 or CD19 alone failed to induce specific target cell lysis, while both antibodies efficiently inhibited bscCD19 Â CD3-mediated lysis in competition experiments. The bscCD19 Â CD3 molecule does not induce lysis of bystander cells, as CD19-negative plasmocytoma cells (XG-1) are not affected by bscCD19 Â CD3-mediated T-cell cytotoxicity in a mixed population with CD19-positive lymphoma cells (NALM-6) (AL, unpublished data). BscCD19 Â CD3-mediated killing is therefore target specific and not simply because of unspecific Tcell activation. To date, functional analyses of bscCD19 Â CD3 have been exclusively performed using cell lines and allogeneic primary T cells from healthy donors. Data with primary lymphoma cells, including B-CLL cells, and autologous T cells from patients treated with cytotoxic drugs, are lacking, and knowledge about the mechanism of action of bscCD19 Â CD3 is limited. Here we show that the bscCD19 Â CD3 induces efficient depletion of primary B cells of healthy donors and NHL patients by autologous T cells even in samples from patients treated with various chemotherapy regimens. We provide evidence that bscCD19 Â CD3 leads to an effective activation of T cells and that bscCD19 Â CD3-induced lymphoma cell depletion is mediated at least in part by a caspase pathway.
Material and methods

Cell samples
Blood samples were obtained from patients with B-cell lymphoma in leukaemic stage after informed consent or from healthy volunteers. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll density gradient centrifugation (Biochrom, Berlin, Germany) and cultured in RPMI1640 Medium (Biochrom) supplemented with 10% fetal calf serum (FCS; Biochrom). PBMC were used either directly or after cryoconservation.
Lymphoma patients' characteristics
Seven of the lymphoma patients were female, 18 male; ages ranged from 49 to 92 years with a median of 62 years. In all, 23 cases analysed were diagnosed as chronic lymphocytic leukaemia of the B-cell type (B-CLL), patient #24 suffered from immunocytoma (IC) and patient #25 from mantle cell lymphoma (MCL). The latter two patients were in a leukaemic stage at the time of blood withdrawal as confirmed by immunophenotyping. Patients' data are summarised in Tables 1 and 2 .
Autologous cytotoxicity assay B cells of healthy donors were purified from PBMC using Dynabeads CD19 and Detachabeads CD19 (Dynal, Oslo, Norway) according to the manufacturer's instructions, labelled with the fluorescent dye PKH26 (Sigma, Deisenhofen, Germany) in accordance with the supplied protocols and adjusted to 1 Â 10 6 cells/ml for cytotoxicity assays. Table 1 In vitro biological activity of bscCD19 Â . All other patients suffered from B-CLL. Therapy status of the patients is indicated: no, untreated; yes, former chemo-or radiotherapy; act, actual therapy (within 3 days prior to obtaining blood samples, see Table 2 ).
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A 96-well flat bottom plate was blocked with PBS/10% FCS (300 ml/well) for 1 h at 371C and rinsed once with PBS. Into each well were seeded: 100 ml of target B cell suspension (1 Â 10 5 cells), 20 ml of medium, bsc17-1A Â CD3+IL-2 or bscCD19 Â CD3, and 80 ml of autologous effector cell suspension (containing 1 Â 10 5 CD3-positive cells), resulting in an E:T ratio of 1:1. The concentrations used were 60 IU/ml IL-2, 10 ng/ ml bscCD19 Â CD3 and 100 ng/ml bsc17-1A Â CD3, in accordance with the higher efficiency of bscCD19 Â CD3 in specific cytotoxicity assays. 27 Plates were centrifuged for 3 min at 190 RCF and incubated for 24 h at 371C and 5% CO 2 in a humidified incubator. Afterwards, cells were stained with propidium iodide (PI, final concentration 20 mg/ml) and analysed on a FACSCalibur flow cytometer for viable and dead PKH26-positive B cells (FL-2 vs FL-3 channels). Correlation to absolute cell numbers was done either by trypan blue exclusion test or by adding Calibrite Beads (Becton Dickinson, San Jose, USA) to each well prior to analysis and counting recovered beads in FACS samples.
Specific lysis was calculated with the formula 100% Â ((number of living B cells in medium control) À (number of living B cells in bsc sample))/(number of living B cells in medium control). In some cases, we found more living B cells in bsc17-1A Â CD3 controls than in medium samples, resulting formally in a negative specific lysis. As there were no statistically significant differences between both controls, these data were defined as 0% specific lysis in Figure 1 .
Lymphoma B-cell depletion assay
The surface of a 24-well plate was blocked by incubation with PBS/10% FCS (1.5 ml/well) for 1 h at 371C, 5% CO 2 , and washed once with PBS. The number of patient PBMC was adjusted to 3 Â 10 6 cells/ml and 1 ml cell suspension was seeded into each well. A measure of 20 ml bscCD19 Â CD3, control antibody bsc17-1A Â CD3 (final concentrations: 50-500 ng/ml), medium as a negative control or phytohaemagluttinin (PHA)+IL-2 as a T cell proliferation control (final concentrations: PHA 2 mg/ml; IL-2 60 IU/ml) were added. The assay was incubated for 5-10 days at 371C and 5% CO 2 . Afterwards, the amounts of T and B cells were measured by FACS as described below. The Table 2 Treatment regimens of study patients 
Figure 1
Autologous cytotoxicity assays with PBMC of healthy donors. B cells of four randomly chosen healthy volunteers were labelled with PKH26 and incubated with autologous T cells alone, with 100 ng/ml bsc17-1A Â CD3+60 IU/ml IL-2 (open bars) or 10 ng/ml bscCD19 Â CD3 (solid bars) for 24 h at E:T ratios of 1:1. Specific lysis was calculated as described in Materials and methods by comparing the amount of living B cells in antibody samples with medium controls. All experiments were carried out in triplicate, error bars indicate standard deviation.
Lymphoma cell depletion by bscCDxCD3
A Löffler et al total number of viable and dead cells was determined by trypan blue exclusion test. B-cell depletion was calculated as 100% Â ((number of living B cells in medium control) À (number of living B cells in bsc sample))/(number of living B cells in medium control). T-cell proliferation was calculated comparing absolute numbers of living T cells in samples at day 0 with bscCD19 Â CD3 samples at the end of depletion assays. Threshold for proliferation was set at a doubling of T cell counts in Table 1 . 
Assessment of surface antigen expression
Assessment of apoptosis
For detection of apoptosis, patient PMBCs were stained with FITC-conjugated annexin V and PI using the annexin V kit (Bender MedSystems, Vienna, Austria) and analysed by flow cytometry according to the manufacturer's instructions. Prior to annexin V-FITC/PI staining B-CLL cells were labelled using a CD19-specific PE-conjugated antibody. To investigate a possible sensitisation of cells to CD95-induced apoptosis, patient PBMC were incubated for 16 h with the anti-CD95 monoclonal IgM antibody CH-11 (1 mg/ml; Beckman Coulter) as previously described.
Assay for intracellular caspase activity and caspase inhibition
Activation of caspases in PBMC was detected using the cellpermeable fluorogenic substrate CaspACE (Promega, Mannheim, Germany) after 3, 4 and 5 days of incubation with or without bsAbs. Briefly, patients' PBMC were stained with CD19-PE antibody, washed with PBS and resuspended in culture medium. Reaction mixtures were then incubated with 10 mM of CaspACE (FITC-VAD-FMK) at 371C for 20 min and, after washing and PI staining, analysed by flow cytometry.
For caspase inhibition experiments, the fluoromethylketonetetrapeptides Z-DEVD-FMK, Z-IETD-FMK and Z-LEHD-FMK (Calbiochem, Nottingham, UK) were used in depletion assays in accordance with protocols described elsewhere. Briefly, caspase inhibitors (10 mM stock solutions in DMSO) were added to cells (0.5 Â 10 6 /well) at the beginning of the experiment at a final concentration of 50 mM.
Results
BscCD19 Â CD3-mediated lysis of primary nonmalignant B cells by autologous T cells
Since CD19 is expressed not only on malignant B cells but also on nearly all developmental stages of normal B cells, a general depletion of patients' B lymphocytes is to be expected during treatment with bscCD19 Â CD3. To assess this side-effect, we analysed T cells of several volunteers for their ability to kill normal autologous B cells in the presence of bscCD19 Â CD3. Figure 1 summarises the results with four healthy donors. As expected, primary B cells are sensitive to bscCD19 Â CD3-mediated lysis. We observed specific cell lysis from 35 up to 84% (Figure 1 , solid bars) in 24-h assays at E:T ratios of 1:1. Target specificity was shown by using the bispecific single-chain antibody 17-1A Â CD3 as a control, which has the same molecular format as bscCD19 Â CD3 but a different target specificity.
28 Bsc17-1A Â CD3 recognises the epithelial cell adhesion molecule EpCAM present on colorectal carcinomas and normal epithelia. Bsc17-1A Â CD3 does not bind to cells negative for both, EpCAM and CD3 29 and fails to induce lysis of B cells. 27 Thus, the experiments with bsc17-1A Â CD3 exclude the possibility that sole binding of the bispecific antibody to T cells elicits T-cell activation and cytotoxicity against B cells. Even in the presence of IL-2, which provides an exogenous Tcell activation signal, bsc17-1A Â CD3 failed to induce B-cell killing (Figure 1, open bars) .
Primary lymphoma B-cell depletion by bscCD19 Â CD3
The high activity of bscCD19 Â CD3 observed with cell lines and primary B cells in assays at low E:T ratios of 2:1 or 1:1 prompted us to investigate its properties with primary B lymphoma cells. To test whether the much lower E:T ratios frequently found in CLL patients can entertain redirected tumour cell lysis, no T-cell enrichment or addition of extra T cells was performed with patients' samples. In the course of the study, blood samples of 25 patients (23 B-CLL, one immunocytoma, one mantle cell lymphoma; see Tables 1 and 2) were analysed in depletion assays. Inclusion of the samples from the mantle cell lymphoma and the immunocytoma patients was possible because these patients were in leukaemic stage at the time of blood withdrawal, containing mainly B cells in the peripheral blood (Table 1) .
T-cell percentages in the PBMC of the patient samples varied from o1 to 26% and the proportion of B cells ranged from 49 to 97% (Table 1 ). This resulted in calculated E:T ratios ranging from 1:3 to 1:90. After an incubation period of 5-10 days, T and B cell levels in the samples were analysed by flow cytometry with CD19-and CD3-specific monoclonal antibodies. To determine the influence of bscCD19 Â CD3 on FACS analysis, competition experiments were performed. The low concentrations of bscCD19 Â CD3 used did not affect staining of the CD3 or the CD19 antigens on cells by the detection antibodies (data not shown).
In addition to FACS analysis, absolute cell numbers in depletion assays were determined using the trypan blue exclusion test. Percentage of B-cell depletion was calculated as the number of viable B cells compared to the medium control (see Material and methods). The FACS data of a representative assay (patient #8) are presented in Figure 2 . The majority of B cells was depleted in the presence of bscCD19 Â CD3, whereas the proportion of T cells increased (Figure 2a and d) . Again, Lymphoma cell depletion by bscCDxCD3 A Löffler et al bsc17-1A Â CD3, which served as a control, failed to induce depletion of B-CLL cells (Figure 2b) . Additionally, we investigated the effect of PHA, which nonspecifically crosslinks surface proteins resulting in T-cell activation, and IL-2 on B-CLL samples. Even in the presence of these strong T-cell activators no lysis of leukaemic B cells could be seen (Figure 2c ), indicating the need for a tight contact between target and effector provided by bscCD19 Â CD3.
BscCD19 Â CD3 alone (without addition of IL-2) induced Tcell proliferation in 22 out of 25 samples with a threshold at two-fold increase in absolute T-cell number in bscCD19 Â CD3 samples at the end of depletion assays compared to samples at day 0 (median 11-fold increase). In 17 samples, an at least fourfold increase of T cells and in 11 samples an increase of at least 10-fold was observed (Table 1 and data not shown).
In 17 cases (16 B-CLL and the immunocytoma sample), B-cell depletion (ranging from 20 to 480%) was achieved without additional T-cell activation by IL-2. When recombinant IL-2 was used as an activation signal, five additional samples (including the sample from the mantle cell lymphoma patient) showed significant cytotoxicity resulting in B-cell depletion in 22 out of 25 PBMC preparations ( Table 1) . Provision of T-cell costimulatory signals via anti-CD28 antibodies had similar effects as addition of IL-2 (data not shown). A total of 14 samples (12 B-CLL, 1 IC, 1 MCL) were derived from patients who had received various chemotherapy regimens with time lags between last treatment and blood withdrawal ranging from 2 days (actual therapy) to more than 2 years (Table 2) . Among these 14 cases, seven showed a good response to bscCD19 Â CD3 without IL-2, the number of responders rising to 11 out of 14 after the addition of IL-2. Even when the last treatment was less than 1 month ago, antibody-mediated depletion of malignant B cells was still efficient in the responsive samples (Table 2 , patients #5, #15, #17 and #20). Malignant B cells from 10 out of 11 untreated patients were sensitive to bscCD19 Â CD3 treatment. All 11 samples were reactive after incubation with IL-2.
In order to determine the minimum amount of bscCD19 Â CD3 necessary for tumour B-cell lysis, we performed antibody titration experiments in the presence or absence of IL-2. Figure 3 shows the results of this analysis for patient sample #7. Despite the low E:T ratio of 1:48 in this sample at day 0, the bscCD19 Â CD3 induced an almost complete depletion of leukaemic B cells within 6 days at a concentration of 5 ng/ml. By adding IL-2 to the assay, the efficacy of bscCD19 Â CD3 could be further enhanced, and even at antibody concentrations of 0.5 ng/ml a significant depletion effect was observed.
Autologous T-cell activation in the presence of bscCD19 Â CD3
T cells of six randomly chosen bscCD19 Â CD3-sensitive PBMC samples (patients #4, #7, #8, #11, #13 and #24) were analysed for expression of activation-specific antigens at day 4 of a depletion assay in the presence of bsc17-1A Â CD3, bscCD19 Â CD3, or PHA and IL-2 as a positive control for unspecific T-cell activation (Figure 4 ). Whereas the Figure 2 FACS data of depletion assay of patient sample #8. PBMC (3 Â 10 6 cells/ml) of patient #8 were incubated either alone (a), with control antibody bsc17-1A Â CD3 (500 ng/ml) and IL-2 (60 IU/ml) (b), PHA (2 mg/ml) and IL-2 (60 IU/ml) (c), or with bscCD19 Â CD3 (500 ng/ml) (d) for 10 days. Viable cells were gated and analysed for expression of CD3 and CD19. E:T ratio at day 0 was 1:45 (2% T cells, 90% B cells). Percentage values of CD19-positive cells are given.
Figure 3
Depletion assay of patient sample #7 at different concentrations of bscCD19 Â CD3 in the presence or absence of IL-2. PBMC (adjusted to 3 Â 10 6 cells/ml at day 0) of patient #7 were incubated for 6 days with bscCD19 Â CD3 at different concentrations in the presence or absence of IL-2 (60 IU/ml) or with the bsc17-1A Â CD3 (500 ng/ml) or PHA (2 mg/ml)+IL-2 (60 IU/ml) as controls. Calculated E:T ratio at day 0 was 1:48 (2% T cells, 96% B cells). Cells were analysed by flow cytometry and viable and dead cells counted after trypan blue staining.
Lymphoma cell depletion by bscCDxCD3
A Löffler et al bsc17-1A Â CD3 induced no alteration of activation markers in comparison to the medium control, the activation marker CD69 was upregulated in four out of six bscCD19 Â CD3-treated samples studied (patients #7, #8, #11 and #13). In three cases (patients #4, #8, and #13), an upregulation of CD25, as well as an increase in cell size was observed. Additionally, T cells from four patients (patients #4, #8, #11 and #13) showed an increased amount of CD38 and CD54 on the cell surface. CD95 expression was upregulated in five out of six patients (patients #4, #8, #11, #13 and #24), although only slightly so in patient #11 (Figure 4) . Collectively, these data provide evidence for phenotypic alterations characteristic of activated T cells, which are induced by bscCD19 Â CD3. However, there were considerable quantitative differences in the expression levels, with the most prominent upregulation pattern seen in patients #8 and #13.
Induction of apoptosis, caspase activation, and CD95 regulation in B-CLL cells in the presence of bscCD19 Â CD3
The mechanism of cell death induced by bscCD19 Â CD3-activated T cells was further investigated. Firstly, we examined PBMC samples of patients #4, #7 and #24 for the presence of B cells, which externalised phosphatidylserine (recognised by annexin V-FITC binding) as an early event of apoptosis. Annexin V-FITC-positive cells were found in all three samples, indicating the involvement of proapoptotic pathways in target cell death. Figure 5a shows the results of this analysis for patient #24 following different incubation times. At day 3 of a depletion assay, there was only a slight difference between bscCD19 Â CD3-treated cells and the negative controls: 6% annexin V-FITC-positive cells in medium, 4% in bsc17-1A Â CD3-treated and 10% in bscCD19 Â CD3-treated samples. However, at day 4 the annexin V-FITC-positive cell population increased to 26% in the bscCD19 Â CD3-treated sample vs 12% and 11% in medium and bsc17-1A Â CD3-treated controls, respectively. After 5 days, 42% of the PI-negative B cells were positive for phosphatidylserine, compared to 10% in both, medium and bsc17-1A Â CD3-treated controls. Additionally, we studied the activation of caspases, a critical event in the apoptotic process, using the cell-permeable fluorogenic pan-caspase substrate CaspACE (FITC-VAD-FMK). Figure 5b shows histograms demonstrating the increase of the Bcell population containing active caspases in the bscCD19 Â CD3-treated sample from 10% at day 3 to 31% at day 4 and 37% at day 5 (corresponding values in the medium control: 6% at day 3, 7% at day 4 and 13% at day 5, and in the bsc17-1A Â CD3-treated control: 4% at day 3, 4% at day 4 and (Table 3) . 28, [30] [31] [32] Apoptosis via the caspase cascade is often induced by CD95 (Fas) ligation. Therefore, we investigated regulation of this antigen on CD19-positive B-CLL cells of the three patients #4, #7 and #24. All three bscCD19 Â CD3-treated samples revealed an upregulation of Fas in the whole B-cell population after 4 days of a depletion assay compared to bsc17-1A Â CD3 controls (Table 4) . However, the agonistic anti-CD95 IgM antibody CH-11 failed to induce apoptosis in leukaemic B cells (data not shown).
Discussion
The limited options in the treatment of therapy-refractory B-CLL have stimulated the search for new immunotherapeutic strategies. Antibodies and antibody conjugates against B lymphocyte differentiation antigens play an increasing role among such strategies. 33, 34 Recently, we have shown that a novel recombinant bispecific single-chain antibody construct, bscCD19 Â CD3, induces rapid and strong lymphoma-directed cytotoxicity mediated by primary T lymphocytes. 26 So far, functional analyses of the bscCD19 Â CD3 using allogeneic T and B cells, have been performed under relatively unphysiological conditions using cell lines, short-time assays and E:T ratios far from what can be achieved in patients. Data with autologous primary B cells (nonmalignant and malignant) and on the underlying killing mechanism of this novel bispecific molecule have been lacking.
Here we show that the bscCD19 Â CD3 is able to induce depletion of primary B cells, mediated by autologous T cells, from all healthy donors investigated, within 24 h, without additional activation of T cells by IL-2 or costimulation by anti-CD28 antibody. These results encouraged us to analyse peripheral blood samples containing malignant B cells from 25 lymphoma patients in leukaemic stage (23 B-CLL, 1 immunocytoma, 1 mantle cell lymphoma). No T-cell enrichment was performed, resulting in E:T cell ratios that closely mimic the in vivo situation. In the majority of cases analysed (17 out of 25, including the immunocytoma), patients' T cells were stimulated to eliminate autologous leukaemic B cells by incubation with bscCD19 Â CD3 alone. In some samples, additional activation of T cells with IL-2 increased these cytotoxic effects and in five of the nonresponding samples (four B-CLL, one mantle cell lymphoma) antibody-mediated lysis could be achieved by IL-2 addition. Thus, 22 out of 25 patient samples showed strong B lymphoma cell depletion after addition of bscCD19 Â CD3 and IL-2. Similar effects to those, generated by the addition of IL-2 were observed, when costimulation was achieved with an anti-CD28 antibody (data not shown). 
Table 3
Involvement of the caspase pathway in B-cell death Percentage values of viable (annexin V-FITC-and PI-negative) CD19-PE-positive cells after 5 days of incubation of patients PBMC either in medium alone, with bscCD19 Â CD3 in the absence or presence of cell-permeable caspase inhibitors with different peptide sequences. All tests were performed in duplicate, mean percentage values are given, standard deviation was always below 10%.
Lymphoma cell depletion by bscCDxCD3 A Löffler et al
In our study, 14 samples were obtained from patients who had previously received chemo-or radiotherapy regimens, with time lags between the last treatment and blood withdrawal ranging from 2 days to more than two years. Remarkably, seven of these cases (50%) showed B-cell elimination with bscCD19 Â CD3 alone and 11 of these cases (73%, including the mantle cell lymphoma and the immunocytoma) showed a good response to bscCD19 Â CD3 in combination with IL-2, with B-cell depletions of more than 50% in our assays. Out of 11, 10 samples from untreated patients included in this investigation were sensitive to bscCD19 Â CD3-mediated cytotoxicity. After addition of IL-2 all untreated patients' samples responded. In contrast, the three resistant samples were obtained from pretreated patients. T cells from two out of these three samples (patients #1 and #3) were stimulated to proliferate by bscCD19 Â CD3, but failed to lyse autologous B-CLL cells. In patient samples #1 and #2 the T-cell proportion was below 1%. Thus, the efficacy of bscCD19 Â CD3-mediated B-cell depletion appeared to correlate with the T-cell proportion at a threshold of around 2% (E:T approximately 1:50). In contrast, patient sample #3 showed no B-cell depletion despite 9% T cells. This patient received chemotherapy until 2 days prior to blood sampling, suggesting a correlation between efficacy of B-cell depletion and current anti-proliferative treatments. We assume that resistance to bscCD19 Â CD3 is either because of a low T-cell proportion (see patients #1 and #2) or actual cytotoxic therapy (patient #3) rather than pretreatment per se. It is noteworthy that five patients were treated with the T-cell-depleting drug fludarabine prior to the depletion assay. Four of these patients' samples showed efficient lysis of leukaemic B cells with bscCD19 Â CD3 + IL-2, in one case (patient #25, MCL), the effect was observed only 43 days after therapy. Two fludarabinetreated samples with a lag time to last treatment of more than 5 months showed B-cell depletion (480%) without IL-2. Thus, while T-cell activity can be achieved by bscCD19 Â CD3 + IL-2 treatment a few weeks after fludarabine therapy, complete regeneration of T-cell functions may take longer. Furthermore, three out of five samples pretreated with chemotherapy regimens without fludarabine less than 1 month (2, 14, 18, 21 and 24 days) prior to blood withdrawal show B-cell depletion activity with bscCD19 Â CD3 without IL-2. The two nonresponders received the last cytotoxic treatment 2 and 14 days prior to blood withdrawal. This indicates that a relatively short time (about 3 weeks) is necessary for adequate T-cell regeneration. Therefore, we would expect bscCD19 Â CD3 to be therapeutically active even in pretreated patients and in combination with various chemotherapy regimens.
The effective T-cell cytotoxicity without additional activation of T cells by IL-2 was surprising in view of the numerous reports on defective T-cell function in B-CLL. [35] [36] [37] [38] [39] Although B-CLLspecific T cells are known to exist in B-CLL patients, as shown in a human/mouse radiation chimera B-CLL model 40 and by induction of lymphokine-activated killer cells reactive against B-CLL, 41 B-CLL T cells seem to be suboptimally activated or anergic, associated with defective IL-2 production by the T cells. While Ayanlar-Batuman et al 35 could completely compensate the defective T-cell proliferative response in their MLR assay with exogenous IL-2, 35 Kay and Kaplan 37 reported only a partial reconstitution of the T-cell proliferative response to mitogens, and Prieto et al 38 showed no correction of the defective T-cell response to PHA, anti-CD3 or PMA by adding exogenous IL-2. Nevertheless, the bscCD19 Â CD3-induced B-CLL-directed Tcell cytotoxicity in the vast majority of B-CLL samples analysed, suggesting that bscCD19 Â CD3-induced stimulation might be efficient to overcome T-cell anergy.
The observed ability of the bscCD19 Â CD3 molecule to mediate lysis of nonmalignant B cells predicts that general Bcell depletion is a potential side effect during bscCD19 Â CD3 treatment. Similar effects after Rituximab treatment are well tolerated by the majority of patients. The depletion of B lymphocytes is transient and the B-cell pool regenerates from haematopoietic stem cells after a certain time. 42, 43 Thus, we assume that depletion of normal B cells is no hindrance for the clinical application of bscCD19 Â CD3.
Efficacy of bsAb constructs at E:T ratios as low as about 1:50 has not previously been described. A conventional CD19 Â CD3 bsAb of the quadroma format was able to induce T-cell proliferation only in the presence of anti-CD28 antibody. In a 4 h chromium release assay after 6 days of prestimulation with conventional CD19 Â CD3 plus anti-CD28 antibody, T cells could lyse approximately 20% of autologous leukaemic B cells at an E:T ratio of 10:1. 44 In another study, the same bsAb-mediated depletion of paediatric B-ALL cells by autologous T cells in three of eight cases analysed. This depletion also required costimulation via anti-CD28-antibodies. 45 A second group reported significant T-cell-mediated killing of primary lymphoma cells after extensive prestimulation (3 weeks with PHA + IL-2 or anti-CD3 + IL-2) at E:T ratios of 9:1-27:1 in a 3.5 h chromium release assay. 46, 47 A recently developed CD19 Â CD3 diabody was able to induce T-cell-mediated killing of autologous CLL cells. However, in this experiment extensive T-cell prestimulation with anti-CD3 antibodies and IL-2 and E:T ratios of 10:1 were necessary. 48 Neither of these antibodies seems to induce cytotoxic effects as efficaciously as bscCD19 Â CD3. Thus, it appears that this novel molecule shows exceptional biological properties within the family of bispecific CD19 Â CD3 antibodies.
In order to better understand the highly efficient killing process and the cellular prerequisites leading to resistance of some samples, we investigated the mechanism of bscCD19 Â CD3-mediated tumour cell elimination. T cells can kill their target cells via induction of apoptosis; therefore, dysregulation of cell death pathways is a potential mechanism of resistance. For instance, it has been demonstrated that resistance of AML cells against immunological effectors might be because of impaired perforin binding to the target cell membrane. 49 Although there is some knowledge about the mechanism of tumour cell destruction by bispecific antibodies from the work of Pfreundschuh and co-workers, 50 ,51 all of these experiments were performed with conventional Fc part-containing bispecific antibodies (CD30 Â CD16), using tumour cell lines as target cells and effector:target cell ratios far from reflecting the in vivo situation. Here we used a depletion assay that more closely mimics the real effector:target cell ratios in patients to analyse the mechanism of bscCD19 Â CD3-mediated T-cell cytotoxicity. Our investigation of the T-cell phenotype demonstrated activation of T cells in the presence of bscCD19 Â CD3 and B cells. This activation, including the generation of large blast cells, was observed after 4 days in depletion assays. In our recently published studies with lymphoma cell lines, the rapid target cell lysis (4 h) was mediated mainly by CD3-positive/ CD8-positive cells at E:T ratios 42:1. 26 In the present autologous lymphoma system, E:T ratios were significantly lower (down to 1:50) and activation of all CD3-positive T cells was observed, indicating different time courses or cytotoxic mechanisms which can be triggered by bscCD19 Â CD3 in different T-cell subpopulations.
Effector T cells use two main pathways to induce target cell death: granule exocytosis (perforin/granzymes) and the death receptor system with Fas (CD95) as its most prominent receptor. 52 Both pathways lead to caspase activation. Whereas CD95-mediated cell death has been shown to be mainly caspase-dependent, granzymes might trigger additional effector cascades to kill a target cell. [53] [54] [55] We could demonstrate that the leukaemic cells in our depletion assays are killed by an apoptotic pathway as shown by annexin V-FITC staining of the target cells, by activation of caspases and by partial inhibition of B-cell depletion with caspase inhibitors.
In our experiments, despite an upregulation of CD95 in the presence of bscCD19 Â CD3, primary B-CLL cells were not susceptible to CD95-mediated apoptosis initiated by the agonistic CD95 IgM antibody CH-11. This is consistent with several studies showing resistance to Fas/FasL-induced apoptosis in B-CLL cells despite an upregulation of CD95 in primary B-CLL cells. [56] [57] [58] Thus, killing of B-CLL cells in our system seems to be independent of Fas, but it is not yet clear whether this effect is due to resistance of malignant B cells as suggested by several groups 58, 59 or to an activation defect of endogenous T cells. Nevertheless, the observed Fas independence suggests the perforin/granzyme system as the major effector pathway in bscCD19 Â CD3-induced B-cell lysis. The described ability of granzyme B to cleave and trigger the caspase system as well as other cellular apoptotic pathways is in accordance with our data, showing partial protection of B lymphocytes by caspase inhibitors. The involvement of perforin and granzymes in bscCD19 Â CD3-mediated cellular cytotoxicity remains to be shown by use of specific inhibitors of these molecules. These questions are currently under investigation in our laboratory.
In summary, we have shown that the bispecific single-chain antibody construct CD19 Â CD3 induces highly efficient T-cellmediated apoptosis of autologous primary normal and malignant B cells at very low E:T ratios, reflecting the clinical situation. Even in samples derived from patients pretreated with different chemotherapy regimens, strong cytotoxic effects of bscCD19 Â CD3 could be observed. In addition, we have provided evidence that B-CLL cell depletion is mediated at least in part by the caspase pathway. Further studies will supply additional information about its mechanism of action and possible resistance pathways. Its properties discriminate bscCD19 Â CD3 from other lymphoma-directed bsAb constructs generated so far and make this molecule a promising agent for the treatment of B-cell malignancies in a clinical setting.
